NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University
Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login